Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 12:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,414 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated Phase 1Phase 2 Interventional Results available

GA-68 DOTA-TOC of Somatostatin Positive Malignancies

NCT02177773
Conditions
Neuroendocrine Tumor, Paraganglioma, Carcinoid Tumors, Neuroblastoma
Interventions
Computed Tomography (CT), Gallium Ga 68-Edotreotide, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
Procedure · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Conditions
Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Epcoritamab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
Timothy Voorhees
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
St Louis, Missouri • Columbus, Ohio
Conditions
Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Assess Fibrin in Brains With AD/ADRD

NCT05336695
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
PET/MR Imaging, 64Cu-FBP8
Diagnostic Test · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Prostate Cancers
Interventions
anti [18F]FACBC
Drug
Lead sponsor
David M. Schuster, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions
rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Breast Cancer
Interventions
Non-contrast Computed Tomography (CT) Scans (Metallic Markers), Non-contrast CT Scans (Metallic Markers)
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Lung Cancers
Interventions
Not listed
Lead sponsor
Everest Detection, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of Lung Cancer Screening in People With Unexplained Weight Loss

NCT06717334
Conditions
Lung Cancer Screening
Interventions
Low Dose CT imaging, blood draws, screening questionnaire
Diagnostic Test · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
50 Years to 80 Years
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Conditions
Glioblastoma
Interventions
Accelerated Hypofractionated Radiation Therapy, Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide, Biospecimen Collection
Radiation · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 5 more
Conditions
ERα+ Breast Cancer, ESR1 Gene Mutation
Interventions
Tamoxifen, FES PET/CT
Drug · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Madison, Wisconsin
Conditions
Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm
Interventions
Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prostate Disease
Interventions
Plastic Scintillation Detectors
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Soft Tissue Metastases, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Ranolazine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Cardiovascular Diseases, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Coronary Artery Disease
Interventions
CT(Computed Tomography) guided Percutaneous Coronary Intervention, IVUS (Intravascular Ultrasound) guided Percutaneous Coronary Intervention
Device
Lead sponsor
Fundación EPIC
Other
Eligibility
18 Years to 85 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Jersey City, New Jersey + 1 more
Conditions
Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Avutometinib, Biopsy, Biospecimen Collection, Computed Tomography, Defactinib, Nivolumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
High Risk Cancer, Lung Cancer
Interventions
Median LCS
Device
Lead sponsor
Median Technologies
Industry
Eligibility
50 Years to 80 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Memphis, Tennessee • Houston, Texas
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Refractory Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib, Ultrasound Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Orange, California • Aventura, Florida + 19 more
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma in Cervical Lymph Node
Interventions
Computed Tomography, Fluciclovine F18, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Coronary Disease
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Royal Oak, Michigan
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Indolent Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, UAE Inhibitor TAK-243
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Esophageal Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 2 Interventional Results available

Reduced Carbohydrate Versus Fat in Obese Subjects

NCT00846040
Conditions
Obesity
Interventions
Reduced fat diet, Reduced carbohydrate diet, Drug: f-18 fallypride, fMRI, PET
Other · Drug · Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Breast Cancer
Interventions
Koning Breast CT
Device
Lead sponsor
Koning Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rochester, New York